PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33828191-3	2021	Here, we developed a bispecific antibody (BsAb; mPEG x HER2) that can easily provide HER2+ tumor tropism to mPEGylated liposomal doxorubicin (PLD) and further increase the drug accumulation in cancer cells via receptor-mediated endocytosis, and improve the cytotoxicity and therapeutic efficacy of HER2+ ovarian tumors.	Doxorubicin	129-140	erb-b2 receptor tyrosine kinase 2	Homo sapiens	55-59	
33828191-3	2021	Here, we developed a bispecific antibody (BsAb; mPEG x HER2) that can easily provide HER2+ tumor tropism to mPEGylated liposomal doxorubicin (PLD) and further increase the drug accumulation in cancer cells via receptor-mediated endocytosis, and improve the cytotoxicity and therapeutic efficacy of HER2+ ovarian tumors.	Doxorubicin	129-140	erb-b2 receptor tyrosine kinase 2	Homo sapiens	85-89